Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.96 |
| ▸ | LMNA | P02545 | 5/20 | 0.96 |
| ▸ | HPGD | P15428 | 4/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | TOP2A | P11388 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofloxacin SCHEMBL1281819 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2325952 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL27004 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL8530004 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2636760 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL23064249 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2465661 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL42310 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL7994990 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL9788110 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12146869-B2 | Methods and compositions for analyte quantification | MATTERWORKS INC (US) | 2024-11-19 | — | — | US | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| US-20240167986-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2024-05-23 | — | — | US | claimed |
| EP-3322482-B1 | TOPICAL CIPROFLOXACIN COMPOSITIONS | TAP PHARMACEUTICALS AG (CH) | 2023-07-26 | — | — | EP | claimed |
| US-20230137741-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | claimed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | claimed |
| CN-116023639-A | Preparation method of medical polyester | 南京鑫航线生物科技有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-113940923-B | Flexible fiber medicine box capable of intelligently releasing medicines and preparation and application thereof | 东华大学 | 2023-04-25 | — | — | CN | claimed |
| CN-114832141-A | Dressing for deep wound treatment and preparation method and application thereof | 衡水市人民医院（哈励逊国际和平医院） | 2022-08-02 | — | — | CN | claimed |
| CN-113940923-A | Flexible fiber medicine box capable of intelligently releasing medicine and preparation and application thereof | 东华大学 | 2022-01-18 | — | — | CN | claimed |
| EP-2740479-A2 | COMPOSITION CONTAINING ANTIBIOTICS AND LYSOPHOSPHATIDYLCHOLINE FOR BOOSTING IMMUNITY OR TREATMENT OF BACTERIAL INFECTIONS | Arimed Inc. (KR) | 2014-06-11 | — | — | EP | claimed |
| US-20140134210-A1 | COMPOSITION CONTAINING ANTIBIOTICS AND LYSOPHOSPHATIDYLCHOLINE FOR BOOSTING IMMUNITY OR TREATMENT OF BACTERIAL INFECTIONS | ARIMED INC. (KR) | 2014-05-15 | — | — | US | claimed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | claimed |
| US-20080300258-A1 | ANHYDROUS CIPROFLOXACIN HYDROCHLORIDE | ALPHORA RESEARCH INC. (CA) | 2008-12-04 | — | — | US | claimed |
| WO-2003103674-A1 | TABLETS COMPRISING CIPROFLOXACIN HYDROCHLORIDE | SHERMAN BERNARD CHARLES (CA) | 2003-12-18 | — | — | WO | claimed |
| US-20030229101-A1 | Mixture containing excipients; microbiocides | SHERMAN BERNARD CHARLES (CA) | 2003-12-11 | — | — | US | claimed |
| EP-1207857-B1 | CIPROFLOXACIN CONTAINING PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2003-06-04 | — | — | EP | claimed |
| WO-2003010144-A2 | A PROCESS FOR SYNTHESIS OF FLUOROQUINOLONIC DERIVATIVES | FARMACEUTSKO-HEMIJSKA INDUSTRIJA 'ZDRAVLJE' (YU) | 2003-02-06 | — | — | WO | claimed |
| EP-1207857-A1 | CIPROFLOXACIN CONTAINING PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Egis Gyogyszergyar Rt. (HU) | 2002-05-29 | — | — | EP | claimed |
| WO-2001012162-A1 | CIPROFLOXACIN CONTAINING PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | EGIS Gyógyszergyár Rt. (HU) | 2001-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134210-A1 | COMPOSITION CONTAINING ANTIBIOTICS AND LYSOPHOSPHATIDYLCHOLINE FOR BOOSTING IMMUNITY OR TREATMENT OF BACTERIAL INFECTIONS | LPCAT1, PHOSPHO1, LPCAT3 | KDM4E 616/4885ALDH1A1 4856/4885LMNA 1014/4885 |
| US-20080300258-A1 | ANHYDROUS CIPROFLOXACIN HYDROCHLORIDE | NQO2, Q6ZSR9, TOP2A | KDM4E 1199/4885ALDH1A1 2152/4885LMNA 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.